Ingmar Hoerr


Also Known As
Founder of CureVac, “the RNA people“

Ingmar Hoerr was chairman of the BOD of CureVac AG and he served as founding CEO for 18 years. In 2000 he founded “CureVac, the RNA people“ together with colleagues in Tübingen, Germany. His entrepreneurship was motivated by his surprising discovery during his doctoral research that naked mRNA is capable to be expressed in vivo without the risk of rapid degradation and the ability of generating strong specific immune responses, in contrary to what had previously been believed. From this key discovery, Ingmar Hoerr, Steve Pascolo and Florian von der Mülbe built up a company that is now the most advanced company in the research and development of mRNA-based drugs. mRNA-based drugs can be developed for a huge variety of diseases and infections. "the RNA people" have worldwide since 2000 an extensive experience in handling and optimizing the versatile molecule RNA for medical purposes. Ingmar triggered the first ever clinical human trials in the space of mRNA and laid the foundation for the whole mRNA industry. The company already has several active ingredients in R&D for the treatment of cancer, the protection against infectious diseases and for protein replacement. Until today, CureVac has tested its mRNA-based products in ten clinical studies with more than 500 human patients and healthy volunteers. Since Ingmar founded CureVac, he and his colleagues raised for the Unicorn approximately $500 million in equity, in total CureVac recieved funding of about $800 million since its inception . CureVac went to NASDAQ August 2020. Ingmar contributed 30+ patents. CureVac has entered into various collaborations with multinational corporations and organizations, including agreements with Boehringer Ingelheim, Novartis, Bayer, Eli Lilly and the Bill & Melinda Gates Foundation.

Voted (0)

Works (0)

Video (0)

News about Ingmar Hoerr(0)

Join our Telegram Channel!